Data from Anti-FDX1 Autoantibody as a Potential Biomarker for Non–Small Cell Lung Cancer Detection

• DOI: 10.1158/1055-9965.c.7700614
• Publication Date: 2025-03-03T08:43:06Z
• Authors: Jing Li; Xiaobin Cao; Lulu Zhang; Aichen Liu; Siyu Liu; Fengqi Chen; Yutong Li; Hanke Ma; Wenke Sun; Songyun Ouyang; Liping Dai; Jingjing Liu
• Keywords: Biomarker Discovery

<div>AbstractBackground:<p>Autoantibodies can be readily identified prior to biopsy and may serve as valuable biomarkers for cancer detection. Ferredoxin 1 (FDX1) is a key regulator in the process of cuproptosis affects prognosis lung cancer. In this study, we investigated whether anti-FDX1 autoantibody could novel biomarker detection non–small cell (NSCLC).</p>Methods:<p>A total 1,155 plasma samples were divided into verification validation groups. The expression levels 414 patients with NSCLC, 327 benign pulmonary nodules (BPN), normal controls (NC) detected using ELISA. Western blotting immunofluorescence analyses performed confirm ELISA results.</p>Results:<p>Plasma significantly higher NSCLC than BPN NCs results confirmed by immunofluorescence. distinguished from NC an AUC (95% confidence interval) 0.806 (0.772–0.839) 0.627 (0.584–0.670), respectively.</p>Conclusions:<p>Our study demonstrated potential benefits detection.</p>Impact:<p>These findings suggested that facilitate NSCLC.</p></div>